Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
Price : $35 *
At a glance
- Drugs Temozolomide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 25 Jan 2016 Planned primary completion date changed from 1 Jun 2014 to 1 Feb 2016, as reported by ClinicalTrials.gov.
- 25 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 25 Jan 2016 Planned end date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.